← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA0Too thin to quote. Widen the cut.
EV / LTM revenue113.5x5.3x9.2x
Premium to unaffected price923%64%103%
Premium to 30-day VWAP0Too thin to quote. Widen the cut.

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
018352009: 1 deals, 0 clean on every measure200912010: 20 deals, 4 clean on every measure2010202011: 20 deals, 8 clean on every measure2011202012: 18 deals, 11 clean on every measure2012182013: 15 deals, 8 clean on every measure2013152014: 23 deals, 10 clean on every measure2014232015: 18 deals, 11 clean on every measure2015182016: 16 deals, 11 clean on every measure2016162017: 19 deals, 15 clean on every measure2017192018: 18 deals, 8 clean on every measure2018182019: 19 deals, 6 clean on every measure2019192020: 13 deals, 4 clean on every measure2020132021: 26 deals, 16 clean on every measure2021262022: 28 deals, 19 clean on every measure2022282023: 26 deals, 12 clean on every measure2023262024: 25 deals, 15 clean on every measure2024252025: 35 deals, 21 clean on every measure2025352026: 22 deals, 11 clean on every measure202622
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Industrials: 14.3x median across 6 dealsIndustrials14.3xn=6Technology: 14.3x median across 6 dealsTechnology14.3xn=6Consumer & Retail: 12.3x median across 7 dealsConsumer & Retail12.3xn=7Materials: 9.9x median across 6 dealsMaterials9.9xn=6
Deals by sector
Healthcare: 25 dealsHealthcare25Technology: 24 dealsTechnology24Financials: 16 dealsFinancials16Industrials: 14 dealsIndustrials14Consumer & Retail: 9 dealsConsumer & Retail9Materials: 9 dealsMaterials9Business Services: 8 dealsBusiness Services8Energy: 8 dealsEnergy8Other: 4 dealsOther4Utilities: 4 dealsUtilities4Media & Telecom: 2 dealsMedia & Telecom2Real Estate: 2 dealsReal Estate2
Deals by buyer type
Financial sponsor: 1 dealsFinancial sponsor1Strategic: 13 dealsStrategic13Management / founder: 0 dealsManagement / founder0Controlling holder: 0 dealsControlling holder0Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 11 dealsUnclassified11
Deals by enterprise value
Under $250m: 13 dealsUnder $250m13$250m to $1bn: 6 deals$250m to $1bn6$1bn to $5bn: 3 deals$1bn to $5bn3$5bn to $20bn: 3 deals$5bn to $20bn3Over $20bn: 0 dealsOver $20bn0Not computed: 0 dealsNot computed0
Deals by industry code
Chemicals, Pharmaceuticals & Allied Products: 16 dealsChemicals, Pharmaceutic…16Instruments, Medical Devices & Optical Goods: 8 dealsInstruments, Medical De…8Health Services: 1 dealsHealth Services1
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Vireo Growth Inc.
2024-12-18 · Public merger · $0.52 a share
Held out of the multiples: EV / LTM EBITDA -0.3x outside 1x to 75x
Deep Roots
Strategic
Healthcare-$7m-0.3x-0.1x
n.a.
DEFM14C
All cash
NeuroMetrix, Inc.
2024-12-17 · Public merger · $4.70 a share
Not named in the filing
Unclassified
Healthcare$9mn.a.2.3x
n.a.
DEFM14A
All cash
Kineta, Inc./de
2024-12-11 · Public merger · $1.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Kayak Mergeco, Inc.
Strategic
Healthcare$10mn.a.n.a.
n.a.
DEFM14A
Includes stock
Arcadium Lithium plc
2024-11-20 (filed) · Public merger · $5.85 a share
Held out of the multiples: EV / LTM EBITDA 129.3x outside 1x to 75x
Not named in the filing
Unclassified
Healthcare$6.9bn129.3x7.6x
103%
DEFM14A
All cash
Avid Bioservices, Inc.
2024-11-06 · Public merger · $12.50 a share
Space Finco, Inc.
Strategic
Healthcare$815mn.a.5.4x
64%
DEFM14A
All cash
Seres Therapeutics, Inc.
2024-08-26 (filed) · Public merger · $1.05 a share
Held out of the multiples: EV / LTM revenue 495.2x above 60x
Not named in the filing
Unclassified
Healthcare$198mn.a.495.3x
n.a.
10% to VWAP
DEFM14A
All cash
SBC Medical Group Holdings Inc
2024-08-12 (filed) · Public merger · $11.50 a share
Mehana Capital, LLC
Financial sponsor
Healthcare$2.3bnn.a.n.a.
n.a.
DEFM14A
All cash
Surmodics Inc
2024-07-08 (filed) · Public merger · $43.00 a share
Held out of the multiples: EV / LTM EBITDA 503.8x outside 1x to 75x
Not named in the filing
Unclassified
Healthcare$605m503.8x5.0x
n.a.
DEFM14A
All cash
Agile Therapeutics Inc
2024-06-25 · Public merger · $1.52 a share
Insud Pharma
Strategic
Healthcare$11mn.a.0.5x
n.a.
DEFM14A
All cash
Alimera Sciences Inc
2024-06-21 · Public merger · $5.50 a share
ANI Pharmaceuticals, Inc.
Strategic
Healthcare$274m26.8x3.0x
n.a.
82% to VWAP
DEFM14A
All cash
Silk Road Medical Inc
2024-06-17 · Public merger · $27.50 a share
Boston Scientific Corporation, Inc.
Strategic
Healthcare$986mn.a.5.3x
n.a.
DEFM14A
All cash
Asensus Surgical, Inc.
2024-06-06 · Public merger · $0.35 a share
KARL STORZ Endoscopy-America, Inc.
Strategic
Healthcare$87mn.a.10.0x
52%
DEFM14A
All cash
Atrion Corp
2024-05-28 · Public merger · $460.00 a share
Nordson Corporation
Strategic
Healthcare$800mn.a.4.5x
n.a.
DEFM14A
All cash
Fusion Pharmaceuticals Inc.
2024-04-25 (filed) · Public merger · $3.00 a share
Held out of the multiples: EV / LTM revenue 68.5x above 60x
Not named in the filing
Unclassified
Healthcare$144mn.a.68.5x
97%
DEFM14A
All cash
Atreca, Inc.
2024-04-22 (filed) · Public merger · $0.17 a share
Not named in the filing
Unclassified
Healthcare-$15mn.a.n.a.
n.a.
DEFM14A
All cash
Shockwave Medical, Inc.
2024-04-04 · Public merger · $335.00 a share
Johnson & Johnson
Strategic
Healthcare$11bnn.a.14.6x
17%
DEFM14A
All cash
Landos Biopharma, Inc.
2024-03-24 · Public merger · $20.42 a share
Held out of the premiums: premium of 161%: distressed or misread
Bespin Subsidiary, LLC, Inc., Inc.
Strategic
Healthcare$26mn.a.n.a.
161%
DEFM14A
All cash
Peak Bio, Inc.
2024-03-04 · Public merger · $10.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 546.5x above 60x
Not named in the filing
Unclassified
Healthcare$219mn.a.546.5x
n.a.
DEFM14A
Includes stock
Atreca, Inc.
2024-02-23 (filed) · Public merger · $0.17 a share
Not named in the filing
Unclassified
Healthcare-$15mn.a.n.a.
n.a.
DEFM14A
All cash
Catalent, Inc.
2024-02-05 · Public merger · $63.50 a share
Creek Parent, Inc.
Unclassified
Healthcare$16bnn.a.4.0x
20%
DEFM14A
All cash
FG Group Holdings Inc.
2024-01-29 (filed) · Public merger · $1.60 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$33m66.4x0.7x
n.a.
DEFM14A
Includes stock
Inhibrx, Inc.
2024-01-22 · Public merger · $5.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 91.9x above 60x
Aventis Inc.
Strategic
Healthcare$166mn.a.91.9x
n.a.
DEFM14A
Includes stock
Axonics, Inc.
2024-01-08 · Public merger · $71.00 a share
Boston Scientific Corporation
Strategic
Healthcare$3.3bnn.a.8.9x
23%
DEFM14A
All cash
Harpoon Therapeutics, Inc.
2024-01-07 · Public merger · $23.00 a share
Not named in the filing
Unclassified
Healthcare$358mn.a.9.6x
118%
DEFM14A
All cash
Ambrx Biopharma, Inc.
2024-01-05 · Public merger · $28.00 a share
Johnson & Johnson
Strategic
Healthcare$1.5bnn.a.n.a.
105%
DEFM14A
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More